Volanesorsen

Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes[1][2][3][4][5].

Product Specifications

CAS Number

[915430-78-3]

Product Name Alternative

ISIS 304801

UNSPSC

12352208

Target

Apolipoprotein

Type

Oligonucleotides

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/volanesorsen.html

Purity

97.97

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

[Volanesorsen]

Molecular Formula

C230H320N63O125P19S19

Molecular Weight

7165.00

References & Citations

[1]Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112 (11) :1479-1490. |[2]Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371 (23) :2200-2206. |[3]Post N, Yu R, Greenlee S, et al. Metabolism and Disposition of Volanesorsen, a 2'-O- (2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019;47 (10) :1164-1173. |[4]Lightbourne M, et al. Volanesorsen, an Antisense Oligonucleotide to Apolipoprotein-CIII, Decreases Triglycerides and Increases Lipoprotein Lipase Activity in Partial Lipodystrophy. Journal of the Endocrine Society, 2021, 5 (Supplement_1) : A305-A305.|[5]Paik J, et al. Volanesorsen: first global approval. Drugs, 2019, 79 (12) : 1349-1354.